To Get Help Now
Click Here
 
Today's Date:

CVS Health Acknowledges Two of its Florida Pharmacies Sold Oxycodone for Illegitimate Purposes, Agrees to Pay Government $22 Million

CVS Health Corp will pay $22 million to settle a three-year federal investigation into whether two of the company’s pharmacies in central Florida sold oxycodone that was not prescribed for legitimate medical purposes.

The U.S. Drug Enforcement Agency (DEA) announced the deal Wednesday, officially bringing an end to the probe. According to a news release posted on the DEA’s website, Florida is the nation’s “epicenter” for the illegal distribution of prescription drugs. Prescription drug addicts were traveling to Florida to find doctors who would write prescriptions for oxycodone, a powerful and potentially addictive painkiller, as well as pharmacies that would fill the prescriptions, despite signs that they were illegitimate prescriptions. The investigation led to the DEA’s execution of administrative inspection warrants at the Sanford, Florida pharmacies. The government revoked the pharmacies’ licenses in June 2012. More CVS Health Acknowledges Two of its Florida Pharmacies Sold Oxycodone for Illegitimate Purposes, Agrees to Pay Government $22 Million

Tipster Wins 30 Percent of $2.2 Million Award After Former Employer Retaliates Against Him for Blowing the Whistle on Prohibited Principal Transactions

Companies that retaliate against whistleblowers may not only be penalized by the U.S. Securities and Exchange Commission (SEC), they may also distribute part of that penalty to the alleged victim of the retaliation.

The SEC did just that on Tuesday when the agency gave a former employee of Paradigm Capital Management Inc. a 30 percent cut of the penalty that his employer had to pay the federal government for allegedly retaliating against him, the first such action in the nation’s history, according to the Wall Street Journal (WSJ). More Tipster Wins 30 Percent of $2.2 Million Award After Former Employer Retaliates Against Him for Blowing the Whistle on Prohibited Principal Transactions

Takeda Announces $2.4 Billion Settlement in Actos Bladder Cancer Cases

In one of the largest product-liability settlements in the pharmaceutical industry, Takeda Pharmaceuticals has agreed to pay $2.4 billion to settle thousands of lawsuits claiming Takeda’s diabetes drug Actos caused bladder cancer.

About 9,000 bladder cancer claims are pending against Takeda, the New York Times reports. Takeda said the settlement would resolve most of the lawsuits involving Actos (pioglitazone). Takeda will take a $2.7 billion charge against earnings to cover the settlement and litigation costs for the remaining cases. More than 3,500 lawsuits brought over Actos have been consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, for pretrial discovery, court dockets indicate. Another 4,500 cases have been filed in state courts in Illinois, West Virginia, California, and Pennsylvania. More Takeda Announces $2.4 Billion Settlement in Actos Bladder Cancer Cases

After Years of Unfixed Problems, FDA Says Medtronic Must Stop Selling Synchromed Drug Pumps

Medtronic Must Stop Selling Synchromed Drug Pumps

Medtronic Must Stop Selling Synchromed Drug Pumps


Medtronic must stop selling the majority of its implantable drug pumps due to years of unfixed problems, the U.S. Food and Drug Administration (FDA) said. Star Tribune reports that the agency has filed a court order stating that Medtronic must stop distributing and producing its Synchromed II drug pumps. The devices are surgically implanted to delivery a drug solution in the area surrounding the spine in patients with cancer, chronic pain and severe muscle spasms. The pumps were recalled because they may lose battery power and fail, causing harm to patients. The devices were also problematic in cases where they delivered the wrong amount of medication. Even though Medtronic has been aware of problems since 2006, they have failed to act; this lack of compliance has prompted to the FDA more aggressively assert its authority. More After Years of Unfixed Problems, FDA Says Medtronic Must Stop Selling Synchromed Drug Pumps

In New York City, an Average of One Passerby per Month is Injured in a Construction Accident

A new Department of Buildings analysis shows that in New York City, an average of one passerby per month is injured in a construction accident.

An average of one passerby per month is injured.


A new Department of Buildings analysis shows that in New York City, an average of one passerby per month is injured in a construction accident.

A Wall Street Journal investigation which focused on passerby injuries, rather than injuries to both construction workers and passersby, found that 96 construction accidents involving passersby occurred between 2008 and 2014, resulting in 155 injuries. More than three-quarters of the accidents happened in Manhattan, according to The Real Deal. More In New York City, an Average of One Passerby per Month is Injured in a Construction Accident

Lawmakers Call on the FDA to ban Amphetamine-like Stimulant Found in Some Dietary Supplements

Lawmakers Call on the FDA to ban Amphetamine-like Stimulant

Lawmakers Call to FDA – ban Amphetamine-like Stimulant


Lawmakers are calling on the U.S. Food and Drug Administration (FDA) to take action against dietary supplement makers who include a potentially dangerous, amphetamine-like stimulant in their products.

BMPEA is an amphetamine-like stimulant first synthesized in the 1930s as a replacement for amphetamine. The chemical has never been tested in humans and is not an authorized dietary supplement ingredient under federal law. Supplement makers have been hiding BMPEA in their products under the name “acacia rigidula,” which is an exotic shrub native to Mexico and southern Texas. Canadian health authorities pulled a popular supplement from store shelves and forced a recall of the product in December, according to The New York Times (The Times.) More Lawmakers Call on the FDA to ban Amphetamine-like Stimulant Found in Some Dietary Supplements

Diabetes Drug Manufacturer Offers $2.2 Billion to Settle Thousands of Lawsuits

Diabetes Drug Manufacturer Offers $2.2B to Settle

Diabetes Drug Manufacturer Offers $2.2B to Settle


The maker of a top diabetes drug that is linked to cancer and other serious health problems has offered to pay more than $2 billion to lay 8,000 lawsuits to rest.

Takeda Pharmaceutical Co., the maker of the drug Actos, has said it will pay $2.2 billion to settle 8,000 lawsuits filed in federal and state courts on behalf of patients who allege that the company hid cancer risks associated with the diabetes medication, court records show. If the offer is accepted, each plaintiff would receive approximately $275,000. More Diabetes Drug Manufacturer Offers $2.2 Billion to Settle Thousands of Lawsuits

Contaminated Duodenoscopes also Linked to Drug-Resistant E. Coli Outbreak

Contaminated Duodenoscopes also Linked to E. Coli Outbreak

Contaminated Duodenoscopes also Linked to E. Coli Outbreak

Tainted duodenoscopes, which have come under scrutiny in light of a series of superbug outbreaks, are also associated with an outbreak of drug-resistant Escherichia coli (E. coli) in a Washington state hospital. According to a study published in Infection Control & Hospital Epidemiology, patients can still be infected even when following manufacturers’ cleaning instructions.

An investigation revealed that between November 2012 and August 2013,32 patients were infected with an antibiotic-resistant strain of E. coli at Seattle Virginia Mason Medical Center. The hospital had followed the manufacturer’s cleaning protocol, but these procedures were apparently insufficient.

Recent evidence suggests that manufacturers’ cleaning instructions alone are not enough to sterilize duodenoscopes, a specialized type of endoscope. Recently, the devices were implicated in recent outbreaks of Carbapenem-resistant Enterobacteriaceae (CRE) at two Los Angeles Hospitals: UCLA’s Ronald Reagan Medical Center and Cedars-Sinai hospital. A total of 11 patients were infected with CRE at the two hospitals and 246 more were potentially exposed.
More Contaminated Duodenoscopes also Linked to Drug-Resistant E. Coli Outbreak

New Deadlines set in Mirena IUD Litigation

New Deadlines set in Mirena IUD Litigation

New Deadlines set in Mirena IUD Litigation


A May 1, 2015 deadline has been set for Bayer Inc. and plaintiffs involved in the Mirena intrauterine device (IUD) litigation to select seven cases to potentially be included in the Second Deposition Pool.

Plaintiffs who wish to have their cases considered for potential inclusion in the Second Deposition Pool must have the Core Criteria in the Plaintiff Fact Sheet completed no later than May 1, 2015, according to a March 17 court order. The Lead Counsel for the Plaintiffs’ Steering Committee (PSC) and Lead Counsel for the Defendants must submit their selections to the court by email by 4:00 p.m. Eastern Standard Time on July 2, 2015. The court order states that these cases should not have unique or idiosyncratic circumstances. Raymond C. Silver, partner at Parker Waichman LLP, has been appointed Co-Lead Counsel in the litigation. More New Deadlines set in Mirena IUD Litigation

Medical Device Maker Facing new Bribery Allegations

Medical Device Maker Facing new Bribery Allegations

Medical Device Maker Facing new Bribery Allegations


Medical device maker Biomet is being investigated by the U.S. Justice Department (D.O.J.) due to fresh bribery allegations.

Prosecutors will extend Biomet’s probation for an additional year, the firm announced earlier this week, in light of recent allegations made by an anonymous whistleblower. According to an email written by the whistleblower, distributors hired by Biomet to sell the company’s orthopedic devices paid kickbacks to government doctors. An internal investigation was launched when Biomet disclosed the email to the government, and several employees at the center of the scandal were fired, according to The New York Times (The Times). More Medical Device Maker Facing new Bribery Allegations